# August Global Partners

August Global Partners is a Private Equity based in Singapore, Singapore.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Singapore, Singapore
- **Region:** Asia
- **Address:** Parkview Square, 600 North Bridge Road, #10-01, Singapore 188778
- **Founded:** 2023
- **Assets under management:** $350M (per firm website)
- **Website:** www.augustglobalpartners.com
- **LinkedIn:** https://www.linkedin.com/company/august-global-partners

## Regulatory record

- **Reports private funds:** No

## About

August Global Partners (AGP) is a growth-oriented fund management company headquartered in Singapore, serving a diverse base of financial investors, conglomerates, and institutions globally. It is a global fund management company with an Asian orientation, investing across healthcare innovation and advanced manufacturing, with emphasis on companies positioned to leverage the growth of Southeast Asia and the wider Asian markets. At inception in 2023, AGP launched two investment vehicles: the AGP Continuation Growth Fund and the AGP Healthcare Fund.

## Sectors

- Digital Health
- AI/ML
- Industrial Tech
- Healthcare Services

## People

- Chu Swee Yeok — Founding Partner
- Basil Lui — CEO & Founding Partner
- Davian Sim — Partner

## Questions

### Who runs investment decisions at August Global Partners?

Founding Partner Chu Swee Yeok and CEO & Founding Partner Basil Lui lead the firm. Chu previously served as CEO of EDBI and founding CEO of Bio*One Capital; Basil Lui led deep-tech, healthcare, and fund investments under her at EDBI. In 2023, Davian Sim — who also joined from EDBI — was made Partner, strengthening the leadership bench for growth equity and advanced manufacturing.

### Does AGP participate in fund commitments or only direct deals?

AGP invests through two dedicated pooled vehicles that make direct growth-stage investments. The website does not describe a fund-of-funds program; the firm's track record is built on direct equity positions in companies such as Ambiq, UltraGreen.ai, and Gene Solutions.

### What investment stages does AGP typically target?

AGP targets growth-stage companies. Its Continuation Growth Fund focuses on growth equity in Southeast Asia-based healthcare services and advanced manufacturing. The Healthcare Fund backs growth-stage companies developing precision medicine, AI-powered health technologies, and patient-centric care solutions.

### How is AGP connected to the Singapore government and EDBI?

Founding Partner Chu Swee Yeok previously led EDBI and Bio*One Capital, both state-backed investment platforms that built Singapore's biomedical ecosystem. AGP itself is an independent commercial entity, though it launched with support from the Singapore government and maintains deep relationships across government-linked research institutions and industry bodies.

### What is AGP's posture on co-investments alongside external GPs?

AGP co-invests alongside strategic and institutional partners. In a US$188 million round for UltraGreen.ai, it invested alongside Temasek-linked 65 Equity Partners and Vitruvian Partners. The firm describes its approach as providing value-added capital and strategic support, often collaborating with specialist co-investors.

### Which sectors does AGP explicitly avoid?

There is no public exclusion list. The firm's stated focus is healthcare innovation and advanced manufacturing. It does not describe mandates in consumer internet, general enterprise SaaS, commodities, or real estate.

## Related profiles

- [AUCTUS Capital Partners](https://altss.com/profile/auctus-capital-partners)
- [Austin Capital Partners](https://altss.com/profile/austin-capital-partners)

---

Last updated: 2026-08-11T15:06:04.815Z

Canonical page: https://altss.com/profile/august-global-partners

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology